Mesoblast (MESO) EBITDA Margin (2014 - 2023)
Mesoblast (MESO) reported EBITDA Margin of 2198.38% for Q2 2023, up 632264.0% on a YoY basis from N/an in Q2 2022, and up 210.03% sequentially from 709.08% in Q1 2023.
Mesoblast (MESO) EBITDA Margin (2014 - 2023) Analysis & Trends
Mesoblast (MESO) has 8 years of EBITDA Margin data on file, last reported at 2198.38% in Q2 2023.
- For the quarter ending Q2 2023, EBITDA Margin rose 632264.0% year-over-year to 2198.38%; the trailing twelve-month figure through Jun 2023 stood at 8116.62% (down 739087.0% YoY), and the FY2025 full-year result was 360.79%, changed N/A from the prior year.
- EBITDA Margin improved to 2198.38% in Q2 2023, from 709.08% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2198.38% in Q2 2023 to a low of 4124.26% in Q2 2022.
- A 5-year average of 493.48% and a median of 216.12% in 2021 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin sank 375908 bps in 2022 and soared 632264 bps in 2023, its largest moves.
- Tracing MESO's EBITDA Margin over 5 years: stood at 1492.89% in 2019, then advanced by 19 bps to 1204.82% in 2020, then soared by 152 bps to 621.1% in 2021, then surged by 60 bps to 992.58% in 2022, then surged by 121 bps to 2198.38% in 2023.
- Business Quant data shows MESO's EBITDA Margin at 2198.38% in Q2 2023, 709.08% in Q1 2023, and 992.58% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 745.71% |
| Mar 31, 2023 | -153.48% |
| Dec 31, 2022 | -650.05% |
| Sep 30, 2022 | -558.27% |
| Jun 30, 2022 | 4.41% |
| Mar 31, 2022 | -417.50% |
| Dec 31, 2021 | -888.15% |
| Sep 30, 2021 | -766.60% |
| Jun 30, 2021 | -711.55% |
| Mar 31, 2021 | -1,157.46% |
| Dec 31, 2020 | -964.93% |
| Sep 30, 2020 | -1,635.86% |
| Jun 30, 2020 | -42.66% |
| Mar 31, 2020 | -648.01% |
| Dec 31, 2019 | -1,180.85% |
| Sep 30, 2019 | -205.07% |
| Jun 30, 2019 | -1,389.17% |
| Mar 31, 2019 | -2,306.24% |
| Dec 31, 2018 | -2,461.38% |
| Sep 30, 2018 | -2,087.85% |